AN-019

CAS No. 879507-25-2

AN-019( —— )

Catalog No. M34157 CAS No. 879507-25-2

AN-019 (NRC-019) is a Bcr-Abl kinase inhibitor with antitumor activity for the study of chronic myelogenous leukemia (CML) and breast cancer.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 686 In Stock
10MG 938 In Stock
25MG 1444 In Stock
50MG 1841 In Stock
100MG 2325 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    AN-019
  • Note
    Research use only, not for human use.
  • Brief Description
    AN-019 (NRC-019) is a Bcr-Abl kinase inhibitor with antitumor activity for the study of chronic myelogenous leukemia (CML) and breast cancer.
  • Description
    AN-019 (NRC-019) is a Bcr-Abl kinase inhibitor with antitumor activity for the study of chronic myelogenous leukemia (CML) and breast cancer.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    Bcr-Abl
  • Recptor
    Bcr-Abl
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    879507-25-2
  • Formula Weight
    517.43
  • Molecular Formula
    C25H17F6N5O
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O=C(NC1=CC=C(C(=C1)NC=2N=CC=C(N2)C3=CN=CC=C3)C)C=4C=C(C=C(C4)C(F)(F)F)C(F)(F)F
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • AKE-72

    AKE-72 is a Pan-BCR-ABL inhibitor with anti-leukemic activity.AKE-72 inhibits the proliferation of Ba/F3 cells expressing natural BCR-ABL or its T315I mutant.

  • CHMFL-ABL-039

    CHMFL-ABL-039 is a type II native ABL kinase and drug-resistant V299L mutant BCR-ABL inhibitor (IC50s: 7.9 nM and 27.9 nM) used in the research of chronic myeloid leukemia.

  • WP1130

    WP1130 (Degrasyn) is a small molecule that specifically and rapidly down-regulates both wild-type and mutant Bcr/Abl protein without affecting bcr/abl gene expression (IC50=1.8 uM).